OMER Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 38.46
- PEG ratio
- 0.81
- P/B
- 8.44
- P/S (TTM)
- 35.33
- EV/EBITDA
- 149.82
Profitability & growth
- ROE (TTM)
- -576.0%
- Operating margin
- 0.3%
- Revenue growth YoY
- 14.9%
- Dividend yield
- —
- Beta
- 2.54
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Omeros Corporation
Company profileOmeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- THE OMEROS BUILDING, SEATTLE, WA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
